Carsgen’s CAR-T Cell Therapy Given Priority Designation in Europe for Multiple Myeloma
CT053, a novel cell-based therapy being developed by Carsgen Therapeutics, was given priority medicines (PRIME) status by the European Medicines Agency (EMA)…
News
Darzalex Combo Increases Response Rates in Newly Diagnosed Multiple Myeloma Patients, Trial Shows
Adding Darzalex (daratumumab) to a combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone — called the VRd combo — increases…
Investigational Antibody GBR 1342 Receives Orphan Drug Designation for Multiple Myeloma
GBR 1342, an investigational bispecific antibody developed by Glenmark Pharmaceuticals, was granted orphan drug designation by the U.S Food and Drug Administration (FDA) for…
Ygalo Continues to Show Promising Activity in Relapsed, Refractory Multiple Myeloma
Ygalo (melflufen) combination therapy continues to demonstrate promising results, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data…
Researchers Identify Promising Target for CAR T-cell Therapy in Myeloma
Designing CAR T-cells to specifically target GPRC5D — a protein appreciably present on the surface of myeloma cells — may be a safe and effective…
Cancer Patients Around the World to Receive Henry Schein ‘Comfort Kits’
Henry Schein, a foundation devoted to promoting dental and medical health, has produced more than 27,000 comfort kits for people fighting cancer in the U.S.
Keytruda Plus Standard Therapy Fails to Improve Outcomes in Multiple Myeloma
The addition of Keytruda (pembrolizumab) to standard therapy — Revlimid (lenalidomide) or Pomalyst (pomalidomide) in combination with dexamethasone…
Israeli Breakthroughs Credited for Early Progress in Treating Multiple Myeloma
Shlomit Norman was 42 when doctors diagnosed her with multiple myeloma — an incurable bone marrow cancer that rarely strikes people under the age…
FDA Grants Orphan Drug Designation to CARsgen’s CT053 for Multiple Myeloma Treatment
The U.S. Food and Drug Administration (FDA) has granted the designation of orphan drug to CT053, one of CARsgen Therapeutics’ lead CAR…
European Commission Approves Empliciti Triple Combo for Advanced Multiple Myeloma
The European Commission (EC) has approved Empliciti (elotuzumab) in combination with Pomalyst (pomalidomide) and low-dose dexamethasone for the treatment…
Recent Posts
- Tuspetinib study in newly diagnosed AML moves to higher dose
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer